Navigation Links
Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants

NEW YORK, June 7,­­­­ 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) announced today the recent issuance of 2,095,204 of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with a private placement that closed in January 2013.  The warrants were exercised at US$ 1.65 per share, resulting in gross proceeds of US$ 3,457,087 for the Company.  As of June 7, 2013 the total number of outstanding common stock is 15,825,394 shares.

"The proceeds from these exercised warrants will be used for the Companies clinical and preclinical programs and for general working capital," said Sergio Traversa, Interim Chief Executive Officer of Actinium Pharmaceuticals.  "This capital will allow us to continue to develop our drug candidates for treatment of the most difficult forms of cancer, including Acute Myeloid Leukemia, where they have made significant advances and already helped a number of patients," added Dragan Cicic, MD, Chief Medical Officer of Actinium Pharmaceuticals.  "The Company intends to advance its programs into late phases of clinical trials and add new programs by the end of 2013."

Shareholders exercised 2,095,204 (67.2%) of the 3,118,988 originally issued A-warrants. 

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc., based in New York, NY, is a biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site or

Segio Traversa, CEO
Actinium Pharmaceuticals Inc.

Dennis S. Dobson Jr.
Tel: (203) 258-0150

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
2. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
3. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
4. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
5. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
6. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
7. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
8. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
9. Actinium Pharmaceuticals Announces New Round of Financing
10. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
11. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
Post Your Comments:
(Date:12/1/2015)... , Dec. 01, 2015 ... addition of the "Medium Molecular Weight ... Lubricants, and Other Applications - Global Industry ... 2015 - 2023" report to their ... announced the addition of the "Medium ...
(Date:12/1/2015)... AMSTERDAM , Dec. 1, 2015 /PRNewswire/ -- ... announced SkyFlow , an X-ray imaging software that ... clinicians decide not to use a grid, at the ... (RSNA) 1 . SkyFlow is Philips, first digital ... for grid-less radiography, which improves clinician,s workflow and supports ...
(Date:12/1/2015)... WASHINGTON , Dec. 1, 2015  Athletic ... its founder have agreed to pay $1.35 million ... deceptively advertised the company,s copper-infused compression clothing would ... by arthritis and other diseases. ... also requires the company and its founder and ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... The Multiple System Atrophy Coalition has announced the launch of ... (MSA) research, timed today to coincide with Giving Tuesday 2015, a global day of ... to work and be productive, to do simple daily activities like walking to the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Henderson, a town of about ... Internet through a partnership this year with Aeneas Internet and Telephone. , With ... destination for entrepreneurs who want to build a business. Whether startups or long ...
(Date:12/1/2015)... ... 01, 2015 , ... Integrated Rental Services (“Integrated Rental”), a ... LLC (“JII”). , With support from JII, Integrated Rental is poised for expansion ... centers, clinics, research labs and medical facilities across the United States. , General ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... for oncology and hematology continuing medical education (CME), today announced that the first ... Grand Hyatt New York. , “The prevention, detection and treatment of gastrointestinal cancers ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one ... Surgery, has been named by MedEsthetics magazine as the Best Single Physician Practice in ... among the many elite aesthetic physicians honored by the industry publication. , Dr. ...
Breaking Medicine News(10 mins):